Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Income towards Parent Company: 2017-2025

Historic Income towards Parent Company for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' Income towards Parent Company fell 69.33% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 54.83%. This contributed to the annual value of -$297.4 million for FY2024, which is 42.19% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Income towards Parent Company of -$130.1 million as of Q3 2025, which was down 12.48% from -$115.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$22.9 million during Q1 2021, with a 5-year trough of -$130.1 million in Q3 2025.
  • For the 3-year period, Crinetics Pharmaceuticals' Income towards Parent Company averaged around -$77.2 million, with its median value being -$74.0 million (2024).
  • Data for Crinetics Pharmaceuticals' Income towards Parent Company shows a maximum YoY tumbled of 75.14% (in 2022) over the last 5 years.
  • Crinetics Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$26.1 million in 2021, then slumped by 75.14% to -$45.7 million in 2022, then decreased by 22.53% to -$55.9 million in 2023, then slumped by 43.69% to -$80.4 million in 2024, then plummeted by 69.33% to -$130.1 million in 2025.
  • Its last three reported values are -$130.1 million in Q3 2025, -$115.7 million for Q2 2025, and -$96.6 million during Q1 2025.